EMJ Gastroenterology 11 [Supplement 9] 2022
This poster review article summarised selected original research covering recent advances in the management of various gastrointestinal diseases, including inflammatory bowel disease, disorders of gut–brain interactions, gastro-oesophageal reflux disease, and pancreatic disorders, presented at the United European Gastroenterology (UEG) Week, which took place in Vienna, Austria, between 8th–11th October 2022.
EMJ Hepatology 10 [Supplement 4] 2022
This symposium took place at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2022, where experts highlighted the importance of communication between healthcare professionals (HCP) and patients with hepatitis B.
EMJ Gastroenterology 11 [Supplement 8] 2022
This mini-review is the fourth in a series exploring TNF inhibitors in treating immune-mediated inflammatory disease. Specifically, this mini-review summarises the evidence of anti-TNFs in Crohn’s disease (CD) complicated by intra-abdominal abscess.
EMJ Neurology 10 [Supplement 2] 2022
Welcome to the EMJ review of the 38th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022 Congress, which took place in Amsterdam, the Netherlands, on 26th–28th October. This review showcases key abstract presentations, including an analysis on the value of serum neurofilament light chain in predicting multiple sclerosis diagnosis and future disability.
EMJ 7.4 2022
We are excited to share the latest issue of EMJ, which covers a multitude of topics across medical disciplines. From the effects of SARS-CoV-2 on people with migraines to umbilical cord haematoma and uterine torsion in pregnancy, and metabolic syndrome, this journal features research articles, case studies, and reviews in fields including microbiology, reproductive health, and diabetes.
EMJ Cardiology 10 [Supplement 8] 2022
Obstructive HCM is a condition in which the heart has thickened walls that are not caused by blockage of the heart valves or by very high blood pressure. For the majority of patients, the cause of their disease has a genetic basis and is hereditary. A genetic test can diagnose HCM in some patients, but the results are inconclusive in others.
EMJ Oncology 10 [Supplement 12] 2022
Cholangiocarcinoma (CCA) is a cancer of the bile duct with poor prognosis and increasing incidence. Filippo de Braud gave an overview of CCA and its classification and highlighted key unmet needs in both diagnosis and treatment. Juan Valle explained that intrahepatic CCA (iCCA) accounts for 11% of the entire cancer of unknown primary (CUP) population, as well as 33% of patients with liver-inclusive disease.